The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNSF.L Regulatory News (NSF)

  • There is currently no data for NSF

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Hardman & Co Research: Non-Standard Finance (NSF): 1H'18 results: jam today, more tomorrow

9 Aug 2018 11:55

Hardman & Co Research Hardman & Co Research: Non-Standard Finance (NSF): 1H'18 results: jam today, more tomorrow 09-Aug-2018 / 11:55 GMT/BST


Hardman & Co: 1H'18 results: jam today, more tomorrow

NSF invested heavily in 2016 to 1H'18, deferring the delivery of greater bottom-line profits. The 1H'18 results delivered tangible payback on this investment, with normalised operating profits up 79% (statutory operating profit moved from a loss of £1.1m to a profit of £7.0m). Pre-tax profits were held back by the group locking in long-term, more expensive, funding (finance costs £9.6m vs. £3.1m) but, as these funds are deployed, pre-tax profits are expected to rise. We reviewed Everyday Loans (EL) in "A heart of gold". We believe the re-pricing and volume opportunities that NSF have in a downturn provide it with counter-cyclicality.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/non-standard-finance/09.08.18-1h18-results-jam-today-more-tomorrow.pdf

To contact us: Hardman & Co 35 New Broad Street London EC2M 1NH www.hardmanandco.comFollow us on Twitter @HardmanandCo Contacts: Mark Thomas +44 20 7194 7622 mt@hardmanandco.com

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

712645 09-Aug-2018 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
10th Jul 20237:00 amRNSNotice of Delisting
7th Jul 20238:06 amRNSSuspension of Trading in Ordinary Shares
5th Jul 20233:18 pmRNSUpdate on Delisting and Suspension of Shares
23rd Jun 20232:51 pmRNSFiling of Annual General Meeting Resolutions
23rd Jun 20232:49 pmRNSResult of AGM
23rd Jun 20237:00 amRNSUpdate on Scheme, Delisting & Directorate Change
23rd May 20237:00 amRNSStandard form for notification of major holdings
18th May 20237:00 amRNSProposed Recapitalisation & Directorate Change 
28th Apr 20235:51 pmRNSReplacement: Update on scheme of arrangement
28th Apr 20233:33 pmRNSUpdate on scheme of arrangement
28th Apr 20238:21 amRNSAudited full year results to 31 December 2022
14th Apr 20237:00 amRNSProposed Release of Debt and Directorate Change
4th Apr 20234:14 pmRNSDirector/PDMR Shareholding
29th Mar 20234:35 pmRNSPrice Monitoring Extension
23rd Mar 20234:35 pmRNSPrice Monitoring Extension
17th Mar 20237:39 amRNSLaunch of Scheme & Proposed Recapitalisation
17th Mar 20237:00 amRNSScheme of Launch & Proposed Recapitalisation
13th Feb 20237:00 amRNS2022 Trading Statement
4th Jan 202310:15 amRNSDirector/PDMR Shareholding
3rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
3rd Jan 20234:35 pmRNSPrice Monitoring Extension
4th Oct 20224:40 pmRNSSecond Price Monitoring Extn
4th Oct 20224:35 pmRNSPrice Monitoring Extension
29th Sep 20225:50 pmRNSDirector/PDMR Shareholding
29th Sep 20224:40 pmRNSSecond Price Monitoring Extn
29th Sep 20224:37 pmRNSPrice Monitoring Extension
28th Sep 20227:05 amRNSUpdate on Current Status and Regulatory matters
28th Sep 20227:05 amRNSUnaudited Half Year Results to 30 June 2022
27th Jul 20224:41 pmRNSSecond Price Monitoring Extn
27th Jul 20224:36 pmRNSPrice Monitoring Extension
22nd Jul 20224:40 pmRNSSecond Price Monitoring Extn
22nd Jul 20224:35 pmRNSPrice Monitoring Extension
19th Jul 20224:41 pmRNSSecond Price Monitoring Extn
19th Jul 20224:35 pmRNSPrice Monitoring Extension
6th Jul 20224:40 pmRNSSecond Price Monitoring Extn
6th Jul 20224:36 pmRNSPrice Monitoring Extension
4th Jul 20224:16 pmRNSDirector/PDMR Shareholding
15th Jun 20223:25 pmRNSFunding facilities update
26th May 20224:42 pmRNSFilings of AGM Resolutions
26th May 20222:49 pmRNSResults of Annual General Meeting
29th Apr 202212:00 pmRNSDirectorate Change
29th Apr 20227:00 amRNSAudited full year results to 31 December 2021
29th Apr 20227:00 amRNSAudited full year results to 31 December 2021
1st Apr 20224:40 pmRNSSecond Price Monitoring Extn
1st Apr 20224:35 pmRNSPrice Monitoring Extension
29th Mar 20229:26 amRNSDirector/PDMR Shareholding
17th Mar 20224:41 pmRNSSecond Price Monitoring Extn
17th Mar 20224:36 pmRNSPrice Monitoring Extension
16th Mar 20224:41 pmRNSSecond Price Monitoring Extn
16th Mar 20224:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.